Literature DB >> 18951217

Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.

Hee Seung Kim1, Noh Hyun Park, Hyun Hoon Chung, Jae Weon Kim, Yong Sang Song, Soon Beom Kang.   

Abstract

OBJECTIVE: To investigate preoperative serum CA-125 levels as a predictive factor for evaluation of lymph node metastasis in epithelial ovarian cancer.
DESIGN: Retrospective study.
SETTING: Medical records at Seoul National University Hospital. POPULATION: Ninety-nine patients with epithelial ovarian cancer between January 2004 and March 2007.
METHODS: The significance of the preoperative serum CA-125 level for the prediction of lymph node metastasis was determined using the receiver operating characteristic (ROC) curve, McNemar's test and logistic regression analysis. Clinical prognostic factors affecting survival were evaluated using the Kaplan-Meier analysis with the log-rank test and Cox's proportional hazard analysis.
RESULTS: The ROC curve showed the best cut-off value (535 U/mL) of the preoperative serum CA-125 level with regard to sensitivity (70.0%) and specificity (83.1%). Imaging studies combined with the preoperative serum CA-125 level showed the highest sensitivity (90.0%), whereas imaging studies alone showed the highest specificity (89.8%) for the prediction of lymph node metastasis. FIGO stage III-IV, the preoperative serum CA-125 level (> or =535 U/mL) and lymph node involvement on imaging studies were significant factors for the prediction of lymph node metastasis (p<0.05). Suboptimal debulking surgery and lymph node metastasis were poor prognostic factors for progression-free survival and overall survival, respectively (p<0.05).
CONCLUSIONS: The preoperative serum CA-125 level (> or =535 U/mL) may be important for the prediction of lymph node metastasis in patients with epithelial ovarian cancer. Furthermore, it can be helpful in selecting patients who should undergo systemic lymphadenectomy for the detection of hidden lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18951217     DOI: 10.1080/00016340802478158

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  11 in total

1.  Overexpression of ASAP1 is associated with poor prognosis in epithelial ovarian cancer.

Authors:  Teng Hou; Chenlu Yang; Chongjie Tong; Huiting Zhang; Juan Xiao; Jundong Li
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

2.  The significance of lymphatic space invasion and its association with vascular endothelial growth factor-C expression in ovarian cancer.

Authors:  Takeshi Hisamatsu; Seiji Mabuchi; Tomoyuki Sasano; Hiromasa Kuroda; Ryoko Takahashi; Yuri Matsumoto; Mahiru Kawano; Katsumi Kozasa; Kei Takahashi; Kenjiro Sawada; Koji Matsuo; Yutaka Tamada; Eiichi Morii; Yasuhiko Kitadai; Tadashi Kimura
Journal:  Clin Exp Metastasis       Date:  2015-10-06       Impact factor: 5.150

3.  CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.

Authors:  Xiaoxiang Chen; Jing Zhang; Wenjun Cheng; Doo Young Chang; Jianfei Huang; Xuan Wang; Lizhou Jia; Daniel G Rosen; Wei Zhang; Da Yang; David M Gershenson; Anil K Sood; Robert C Bast; Jinsong Liu
Journal:  Int J Gynecol Cancer       Date:  2013-06       Impact factor: 3.437

4.  Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.

Authors:  Sai Kiran Sharma; Kuntal K Sevak; Sebastien Monette; Sean D Carlin; James C Knight; Frank R Wuest; Evis Sala; Brian M Zeglis; Jason S Lewis
Journal:  J Nucl Med       Date:  2016-02-02       Impact factor: 10.057

5.  Can CA-125 predict lymph node metastasis in epithelial ovarian cancers in Turkish population?

Authors:  Sinem Sudolmuş; Nadiye Köroğlu; Gökhan Yıldırım; Volkan Ülker; Ahmet Gülkılık; Ramazan Dansuk
Journal:  Dis Markers       Date:  2014-03-25       Impact factor: 3.434

6.  Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study.

Authors:  Juan Zhou; Zhen-Yu He; Feng-Yan Li; Jia-Yuan Sun; Huan-Xin Lin; San-Gang Wu; Qiong-Hua Chen
Journal:  Oncotarget       Date:  2016-02-16

7.  Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.

Authors:  Ali Ayhan; Nazlı Topfedaisi Ozkan; Mustafa Erkan Sarı; Husnu Celik; Murat Dede; Özgür Akbayır; Kemal Güngördük; Hanifi Şahin; Ali Haberal; Tayfun Güngör; Macit Arvas; Mehmet Mutlu Meydanlı
Journal:  J Gynecol Oncol       Date:  2018-01       Impact factor: 4.401

8.  Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer.

Authors:  Xia Xu; Yan Wang; Fang Wang; Lizhou Jia; Yiqin Zhou; Fei Deng; Junwei Qu; Bifang Zhou; Aifeng Meng; Bole Fu; Xiaoxiang Chen; Zhiying Qian; Jinhua Wang
Journal:  J Ovarian Res       Date:  2013-04-25       Impact factor: 4.234

9.  Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer.

Authors:  Daye Cheng; Bin Liang; Yunhui Li
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240

10.  Creation and validation of models to predict response to primary treatment in serous ovarian cancer.

Authors:  Jesus Gonzalez Bosquet; Eric J Devor; Andreea M Newtson; Brian J Smith; David P Bender; Michael J Goodheart; Megan E McDonald; Terry A Braun; Kristina W Thiel; Kimberly K Leslie
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.